These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20050879)

  • 1. Industry sponsorship and selection of comparators in randomized clinical trials.
    Lathyris DN; Patsopoulos NA; Salanti G; Ioannidis JP
    Eur J Clin Invest; 2010 Feb; 40(2):172-82. PubMed ID: 20050879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disclosure of competing financial interests and role of sponsors in phase III cancer trials.
    Tuech JJ; Moutel G; Pessaux P; Thoma V; Schraub S; Herve C
    Eur J Cancer; 2005 Oct; 41(15):2237-40. PubMed ID: 16214044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor.
    Flacco ME; Manzoli L; Boccia S; Capasso L; Aleksovska K; Rosso A; Scaioli G; De Vito C; Siliquini R; Villari P; Ioannidis JP
    J Clin Epidemiol; 2015 Jul; 68(7):811-20. PubMed ID: 25748073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.
    Privitera M
    Epilepsy Res; 2006 Jan; 68(1):52-6. PubMed ID: 16377139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006.
    Naldi L; Svensson A; Zenoni D; Diepgen T; Elsner P; Grob JJ; Coenraads PJ; Bouwes Bavinck JN; Maccagni A; Linder D; Williams H;
    Br J Dermatol; 2010 Feb; 162(2):384-9. PubMed ID: 19785620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Industry sponsorship and authorship of clinical trials over 20 years.
    Buchkowsky SS; Jewesson PJ
    Ann Pharmacother; 2004 Apr; 38(4):579-85. PubMed ID: 14982982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of industry sponsorship to published outcomes in gastrointestinal clinical research.
    Brown A; Kraft D; Schmitz SM; Sharpless V; Martin C; Shah R; Shaheen NJ
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1445-51. PubMed ID: 17101295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating solutions to sponsorship bias.
    Doucet M; Sismondo S
    J Med Ethics; 2008 Aug; 34(8):627-30. PubMed ID: 18667655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sponsorship and design characteristics of trials registered in ClinicalTrials.gov.
    Roumiantseva D; Carini S; Sim I; Wagner TH
    Contemp Clin Trials; 2013 Mar; 34(2):348-55. PubMed ID: 23380028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective.
    Rosenblatt M
    J Bone Miner Res; 2003 Jun; 18(6):1142-5. PubMed ID: 12817772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and factors associated with use of placebo control groups in randomized controlled trials in psoriasis: a cross-sectional study.
    Katz KA; Karlawish JH; Chiang DS; Bognet RA; Propert KJ; Margolis DJ
    J Am Acad Dermatol; 2006 Nov; 55(5):814-22. PubMed ID: 17052487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
    Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical company-sponsored drug trials: what are we to believe?
    Shekelle P
    J Clin Epidemiol; 2010 Feb; 63(2):126-7. PubMed ID: 19836207
    [No Abstract]   [Full Text] [Related]  

  • 14. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Data bases of clinical trials.
    Albrich JM
    N Engl J Med; 1999 Jan; 340(1):65-6. PubMed ID: 9882223
    [No Abstract]   [Full Text] [Related]  

  • 16. [Are treatment effects or adverse effects of significance for the association between financing and conclusions in randomized trials?].
    Als-Nielsen BE; Chen W; Gluud CN; Gluud LL
    Ugeskr Laeger; 2004 Apr; 166(18):1676-8. PubMed ID: 15174406
    [No Abstract]   [Full Text] [Related]  

  • 17. Progress and problems for randomized clinical trials: from streptomycin to the era of megatrials.
    Hilbrich L; Sleight P
    Eur Heart J; 2006 Sep; 27(18):2158-64. PubMed ID: 16870690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmaceutical companies as sponsors of clinical trials--advantages and limitations].
    Reis LL
    Rev Port Cardiol; 1992 Apr; 11(4):333-8. PubMed ID: 1632988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spine device clinical trials: design and sponsorship.
    Cher DJ; Capobianco RA
    Spine J; 2015 May; 15(5):1133-40. PubMed ID: 25637470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design.
    Goswami ND; Tsalik EL; Naggie S; Miller WC; Horton JR; Pfeiffer CD; Hicks CB
    Trials; 2014 Jan; 15():31. PubMed ID: 24450313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.